MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
9.88
+0.27
+2.79%
Opening 11:38 07/08 EDT
OPEN
9.72
PREV CLOSE
9.61
HIGH
10.17
LOW
9.72
VOLUME
533.24K
TURNOVER
--
52 WEEK HIGH
11.78
52 WEEK LOW
5.79
MARKET CAP
1.57B
P/E (TTM)
-8.6012
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OCUL last week (0630-0704)?
Weekly Report · 1d ago
Weekly Report: what happened at OCUL last week (0623-0627)?
Weekly Report · 06/30 10:59
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
Barchart · 06/26 12:54
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
Benzinga · 06/24 16:30
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Ocular Therapeutix (OCUL) and Vertex Pharmaceuticals (VRTX)
TipRanks · 06/23 13:10
Weekly Report: what happened at OCUL last week (0616-0620)?
Weekly Report · 06/23 10:52
Ocular's Make-Or-Break Moment: Axpaxli Data Looms For Wet AMD Market (Upgrade)
Seeking Alpha · 06/16 19:37
Weekly Report: what happened at OCUL last week (0609-0613)?
Weekly Report · 06/16 10:58
More
About OCUL
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.